


# SAFETY DATA SHEET

## Scanda

### Section 1: Identification of the Substance and Supplier

|                            |   |
|----------------------------|---|
| <b>Product name</b>        | <b>Scanda</b>   |
| <b>Recommended use</b>     | Oral drench for the management of internal parasites in sheep & cattle  |
| <b>Company details</b>     | <b>Schering-Plough Animal Health Ltd</b><br><b>33 Whakatiki Street, Upper Hutt 5018, New Zealand</b><br><br>Phone: 0800 800 543 Fax: 0800 808 100<br>Website: <a href="http://www.coopersonline.co.nz">www.coopersonline.co.nz</a><br>Hours: 8 am – 5 pm, Mon – Fri |
| <b>Emergency telephone</b> | <b>0800 764 766 (0800 POISON) 24 hours human health</b><br><b>0800 243 622 (0800 CHEMCALL) 24 hours</b>   |
| <b>Date of preparation</b> | April 2019  |

### Section 2: Hazards Identification

|                               |   |
|-------------------------------|---|
| <b>Hazard classifications</b> | 6.1E: Acute toxicant<br>6.4A: Eye irritant<br>6.5B: Contact sensitiser<br>6.6B: Mutagen<br>6.8B: Reproductive/Developmental toxicant<br>6.9B: Target organ systemic toxicant<br>9.1B: Aquatic ecotoxicant   |
| <b>GHS Pictogram:</b>         |    |
| <b>Signal word</b>            | Warning   |
| <b>Hazard statement</b>       | H303: May be harmful if swallowed.<br>H317: May cause an allergic skin reaction.<br>H320: Causes eye irritation.<br>H341: Suspected of causing genetic defects from repeated oral exposure.<br>H361: Suspected of damaging fertility or the unborn child from repeated oral exposure.<br>H373: May cause damage to the liver, blood and the haematopoietic systems through prolonged or repeated oral exposure at high doses.<br>H411: Toxic to aquatic life with long lasting effects. |
| <b>Prevention statement</b>   | P102: Keep out of reach of children.<br>P202: Do not handle until all safety precautions have been read and understood.<br>P260: Do not breathe mist.<br>P264: Wash contacted areas thoroughly after handling.<br>P272: Contaminated work clothing should not be allowed out of the workplace.<br>P273: Avoid release to the environment.<br>P280: Wear protective gloves, protective clothing and eye or face protection.<br>P281: Use personal protective equipment as required.      |

# Scanda

**Response statement**

P101: If medical advice is needed, have product container or label at hand.  
 P302+P352: IF ON SKIN: Wash with plenty of soap and water.  
 P305 + P351 + P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.  
 P308+P313: If exposed or concerned: Get medical advice.  
 P314: Get medical advice/attention if you feel unwell.  
 P321: See first aid instruction on the registered label.  
 P333 + P313: If skin irritation or rash occurs: Get medical advice/attention.  
 P337 + P313: If eye irritation persists: Get medical advice/attention.  
 P362 + P364: Take off contaminated clothing and wash before reuse.  
 P391: Collect spillage.

**Storage** P405: Store locked up.

**Disposal** P501: Dispose of product, packaging and waste at an approved landfill or other approved facility.

## Section 3: Composition/Information on Ingredients

| Chemical name            | CAS number | Concentration |
|--------------------------|------------|---------------|
| Levamisole Hydrochloride | 16595-80-5 | 8%            |
| Oxfendazole              | 53716-50-0 | 4.53%         |
| Sorbic Acid NF           | 110-44-1   | <1%           |
| Citric Acid              | 77-92-9    | <10%          |

## Section 4: First Aid Measures

**Necessary first aid measures**

**SKIN CONTACT** While wearing protective gloves, carefully remove any contaminated clothing, including shoes, and wash skin thoroughly with soap and water. If irritation or symptoms occur or persist, consult a doctor.

**EYE CONTACT** Immediately rinse eyes thoroughly with plenty of water. If wearing contact lenses, remove only after initial rinse, and continue rinsing eyes for at least 15 minutes. If irritation occurs or persists, consult a doctor.

**INGESTION** Rinse mouth and drink a glass of water. Do not induce vomiting unless under the direction of a qualified medical professional or Poison Control Centre. If symptoms persist, consult a doctor.

**INHALATION** Remove to fresh air. If any trouble breathing, get immediate medical attention. Administer artificial respiration if breathing has ceased. If irritation or symptoms occur or persist, consult a doctor.

**Required instructions** For advice contact the National Poisons Centre 0800 POISON (0800 764 766) or a doctor.

**Notes for medical personnel** The information presented below pertains to the following individual ingredients, and not to the mixture(s). Only information about the ingredients that are expected to contribute significantly to the potential health hazard profile of the formulation(s) are presented:

Levamisole is an anthelmintic and immunostimulant. Acute exposure to

## Scanda

levamisole may cause nausea, vomiting, diarrhoea, abdominal pain, dizziness, or headache. Chronic exposure may cause hypersensitivity reactions including fever, flu-like syndrome, arthralgia, muscle pain, skin rashes, or cutaneous vasculitis, CNS effects including headache, insomnia, dizziness, or convulsions, haematological abnormalities including agranulocytosis, leucopenia, or thrombocytopenia, or gastrointestinal effects including abnormal taste in the mouth.

Oxfendazole is not-irritating, not-sensitizing, and practically not-toxic acutely. Based on animal studies, oxfendazole may cause liver, bone marrow, testes, gastrointestinal tract, and blood cell effects following chronic exposure.

**Workplace facilities**      Emergency showers and eyewashes may be warranted depending on quantity and type of use.

### Section 5: Fire Fighting Measures

|  |  |
|--|--|
| <b>Type of hazard</b>                  | Not classified as flammable  |
| <b>Fire hazard properties</b>          | No information available   |
| <b>Regulatory requirements</b>         | No information available   |
| <b>Extinguishing media and methods</b> | Carbon dioxide (CO <sub>2</sub> ), extinguishing powder or water spray.      |
| <b>Hazchem code</b>                    | 3Z (Contain spillage)  |
| <b>Recommended protective clothing</b> | Wear full protective clothing and self-contained breathing apparatus (SCBA). |

### Section 6: Accidental Release Measures

|                                  |   |
|----------------------------------|---|
| <b>Personal Precautions</b>      | Avoid contact with skin, eyes and clothing. Do not touch damaged containers or spilled material unless wearing appropriate protective clothing.   |
| <b>Environmental Precautions</b> | Prevent spilled material from flowing onto adjacent land or into streams, ponds, or lakes. Avoid release to the environment.  |
| <b>Emergency procedures</b>      | Wear chemical resistant gloves and overalls, facemask or goggles. Prevent further spillage. Adsorb spilled product and place in sealable container for disposal. Wash down affected area with water plus detergent. Absorb and collect washings and place in the same sealable container for disposal. Seek advice from the local authority regarding disposal. |

## Scanda

### Section 7: Handling and Storage

|                                      |  |
|--------------------------------------|--|
| <b>Precautions for safe handling</b> | Avoid contact with skin, eyes, and mucosa. Keep containers adequately sealed during material transfer, transport, or when not in use. See Section 8 (Exposure Controls) for additional guidance.                                 |
| <b>Regulatory requirements</b>       | Signage required where quantities greater than 1000L are present.<br>Secondary containment required where quantities greater than 1000L are present.<br>Emergency Plan required where quantities greater than 1000L are present. |
| <b>Handling practices</b>            | Avoid contact with skin. Keep containers adequately sealed during material transfer, transport, or when not in use.  |
| <b>Certified handlers</b>            | Not required   |
| <b>Conditions for safe storage</b>   | Store in original container in a cool, dry, ventilated place away from direct heat or direct sunlight. Keep container sealed when not in use. Keep out of reach of children.   |
| <b>Store site requirements</b>       | Store in a cool dry place at room temperature (i.e. 5°C to 25°C).  |
| <b>Packaging</b>                     | PG III   |

### Section 8: Exposure Control/Personal Protection

|   |  |
|---|--|
| <b>Occupational exposure limits</b>             | Propylene glycol TWA (vapour & particulates) 150ppm (474mg/m <sup>3</sup> )  |
| <b>Application in the workplace</b>             | Ensure adequate ventilation. Keep container sealed when not in use.  |
| <b>Exposure standards outside the workplace</b> | No TEL is set for this substance at this time<br>No EEL is set for this substance at this time   |
| <b>Personal protection</b>                      | Wear chemical resistant gloves, facemask or goggles.   |
| <b>Engineering controls</b>                     | The health hazard risks of handling this material are dependent on many factors, including physical form, duration and frequency of process or task, and effectiveness of engineering controls. Site-specific risk assessments should be conducted to determine the feasibility and the appropriateness of all exposure control measures. Exposure controls for normal operating or routine procedures follow a tiered strategy. Engineering controls are the preferred means of long-term or permanent exposure control. If engineering controls are not feasible, appropriate use of personal protective equipment (PPE) may be considered as alternative control measures. Exposure controls for non-routine operations must be evaluated and addressed as part of the site-specific risk assessment. |

### Section 9: Physical and Chemical Properties

|   |                          |
|---|--------------------------|
| <b>Appearance</b>                                   | White suspension         |
| <b>Odour</b>  | No information available |
| <b>Odour threshold</b>                              | No information available |
| <b>pH</b>   | No information available |
| <b>Melting point/freezing point</b>                 | No information available |
| <b>Initial boiling point and boiling range</b>      | 100°C                    |
| <b>Flash point</b>                                  | No information available |
| <b>Flammability (solid, gas)</b>                    | No information available |
| <b>Upper/lower flammability or explosive limits</b> | No information available |
| <b>Vapour pressure</b>                              | No information available |
| <b>Vapour density</b>                               | No information available |
| <b>Relative density</b>                             | 1.055 at 20°C            |
| <b>Solubility (ies)</b>                             | Emulsifiable             |
| <b>Partition coefficient: n-octanol/water</b>       | No information available |
| <b>Auto-ignition temperature</b>                    | No information available |
| <b>Decomposition temperature</b>                    | No information available |
| <b>Kinematic viscosity</b>                          | No information available |

### Section 10: Stability and Reactivity

|   |  |
|---|--|
| <b>Stability of the substance</b>       | Stable under normal conditions.  |
| <b>Conditions to avoid</b>              | Avoid high temperatures.   |
| <b>Material to avoid</b>                | Avoid food products.   |
| <b>Hazardous decomposition products</b> | Carbon oxides (CO <sub>x</sub> ), Sulphur oxides (SO <sub>x</sub> ), and Nitrogen oxides (NO <sub>x</sub> ). |

### Section 11: Toxicological Information

#### Effects for individual ingredients only

|  |   |
|--|---|
| <b>Acute toxicity</b>                    | <p>(Oral)<br/>         Levamisole:<br/>         (Rat/Mouse) LD50 200mg/kg [EPA NZ]<br/>         Sorbic Acid:<br/>         (Rat) LD50 3200mg/kg [EPA NZ]<br/>         Citric acid:<br/>         (Mouse) LD50 5000mg/kg [IUCLID 2000]</p> <p>(Dermal)<br/>         Sorbic Acid:<br/>         (Rabbit) Result: irritating<br/>         (Human) Result: sensitizing, Type: Patch-Test</p> <p>(Inhalation)<br/>         Citric acid:<br/>         Irritating to respiratory system. [EPA NZ]</p>   |
| <b>Aspiration hazard</b>                 | No information available  |
| <b>Respiratory irritation</b>            | No information available  |
| <b>Skin corrosion/irritation</b>         | <p>Sorbic Acid:<br/>         (Human) A severe human and experimental skin irritant. [EPA NZ]<br/>         Citric acid:<br/>         Skin irritation. [EPA NZ]</p>   |
| <b>Serious eye damage/irritation</b>     | <p>Sorbic Acid:<br/>         (Rabbit) Irritating to the eye. [EPA NZ]<br/>         Citric acid:<br/>         (Rabbit) Highly irritating to the eye. [EPA NZ]</p>  |
| <b>Respiratory or skin sensitisation</b> | <p>Sorbic Acid:<br/>         (Human) Contact sensitiser. [EPA NZ]</p>   |
| <b>Germ cell mutagenicity</b>            | <p>Levamisole:<br/>         Induced chromosome gaps and breaks in human lymphocytes in vitro and in vivo after volunteers were given 2 mg/kg. No chromosomal damage occurred in mice given 2.5 mg/kg subcutaneously. [EPA NZ]</p>   |
| <b>Carcinogenicity</b>                   | No information available  |
| <b>Reproductive toxicity</b>             | <p>Oxfendazole:<br/>         Suspected human reproductive or developmental toxicants [EPA NZ]</p>   |
| <b>Specific organ toxicity</b>           | <p>Levamisole:<br/>         EndPoint: LOAEL<br/>         Primary Organ: Blood and the Hematopoietic system<br/>         The commonest and most severe effect induced by levamisole is agranulocytosis. This can be fatal, particularly if infection occurs but it is reversible. It occurs at relatively low doses even when given on non-consecutive days. No NOEL can be identified and if one exists it probably is extremely small. Consequently all MRL of 0.01 mg/kg is recommended.<br/>         ADI of 0-6 ug/kg based on LOAEL of 1.25 mg/kg/day haemolytic effects in dogs,</p> |

## Scanda

|                         |  |
|-------------------------|--|
|                         | <p>safety factor of 200.<br/>MRLs of 100 ug/kg in muscle, kidney and fat, and 100 ug/kg for liver.<br/>Chronic studies in (previously sensitised) dogs showed evidence of haemolytic effects with a LOAEL of 1.25 mg/kg day. [EPA NZ]<br/>Oxfendazole:<br/>Hepatotoxicity/ Alimentary system (liver) effects were observed in rats and mice. The NOEL was 10 mg/kg in the diet, equal to 0.7 mg/kg/bw/day in males and 0.9 mg/kg/bw/day in females. [EPA NZ]</p> |
| <b>Narcotic effects</b> | No information available   |

### Section 12: Ecological Information

#### Effects for individual ingredients only

|                                      |  |
|--------------------------------------|--|
| <b>Aquatic</b>                       | <p>Oxfendazole:<br/>(Daphnia magna) EC50 48-hr 0.52 mg/L [EPA NZ]<br/>Sorbic acid:<br/>Chlorella pyrenoidosa (Algae) EC100- 7 day (168 hr) 5 mg/l [EPA NZ]</p> |
| <b>Terrestrial</b>                   | <p>Levamisole:<br/>(Rat/Mouse) LD50-200 mg/kg [EPA NZ]</p>   |
| <b>Persistence and degradability</b> | <p>Sorbic acid:<br/>95 % after 6 day</p>   |
| <b>Bioaccumulative</b>               | <p>Sorbic acid:<br/>No</p>   |
| <b>Mobility in soil</b>              | <p>Sorbic acid:<br/>3 hour(s) &lt; 10 %</p>  |
| <b>Other adverse effects</b>         | No information available   |


### Section 13: Disposal Considerations

|                             |  |
|-----------------------------|--|
| <b>Disposal information</b> | <p><b>Disposal</b><br/>Dispose of unused contents in a suitable landfill. Where possible, dispose of unused product through AgRecovery Chemicals. Avoid contamination of any water source or the environment with product or empty container.</p> <p><b>Container Disposal</b><br/>Dispose of empty container by puncturing and burying in a suitable landfill. Where possible, recycle through AgRecovery. Do NOT burn.</p> |
| <b>Reference</b>            | Current version of NZS 8409 Management of Agrichemicals  |

# SAFETY DATA SHEET

## Scanda

### Section 14: Transport Information

|  |   |
|--|---|
| <b>UN Number</b>   | 3082  |
| <b>UN proper shipping name</b>                             | ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.<br>(Oxfendazole)              |
| <b>UN dangerous goods class and subsidiary risk</b>        | 9   |
| <b>UN Packaging Group</b>                                  | PG III  |
| <b>Environmental hazards</b>                               | Marine pollutant  |
| <b>Special precautions when transporting the substance</b> |  |

### Section 15: Regulatory Information

|                          |   |
|--------------------------|---|
| <b>Regulatory status</b> | HSNO Approval Code: HSR001846<br>For full listings of controls see <a href="http://www.epa.govt.nz">www.epa.govt.nz</a><br><br>ACVM Registration No: A007130<br>For conditions of registration see <a href="http://www.foodsafety.govt.nz">www.foodsafety.govt.nz</a> |
|--------------------------|---|

### Section 16: Other Information

|                               |                                   |
|-------------------------------|-----------------------------------|
| <b>Additional information</b> | Scanda is a registered trademark. |
|-------------------------------|-----------------------------------|

Schering-Plough Animal Health Ltd known as MSD Animal Health, is a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, USA. Schering-Plough urges each user or recipient of this SDS to read the entire data sheet to become aware of the potential hazards associated with this material. This SDS summarises, at the date of issue, our best knowledge of the health and safety hazard information. Although reasonable care has been taken in the preparation of this document, Schering-Plough Animal Health Ltd extend no warranties and make no representations as to the accuracy or completeness of the information contained therein, and assume no responsibility regarding the suitability of this information for the user's intended purposes or for the consequence of its use. Each individual should make a determination as to the suitability of the information for their particular purpose(s).